Phase II data enough for Aurinia to continue with dry eye therapy VOS

Shares in Canadian immunology specialist Aurinia Pharmaceuticals (TSX: AUP) have fallen over 8% since the firm announced mixed results for its dry eye therapy VOS (voclosporin), in a Phase II head-to-head study against Restasis (cyclosporine).

The study found no statistical difference between VOS and Restasis for the primary endpoint, with both drugs exhibiting low drop discomfort scores. Both drugs were also well-tolerated.

However, the firm emphasized statistically-significant improvements over Restasis at week 4, according to pre-specified secondary endpoints which are “FDA-accepted efficacy endpoints.”